Oxford Glycosciences pic (OGS) (Oxford, U.K.) says it will now recommend to its shareholders Celltech Group pic's (Slough, Berkshire, U.K.) 101.4 million pound takeover offer, although the OGS board still believes the offer does not reflect the value of the business and cash the company has. OGS had been talking to several other companies, including Cambridge Antibody Technology Group pic (CAT) (Cambridge, U.K.), but says that since making its offer in January, CAT'S share price has dropped too low(from 540 pence/share to 349.5 pence/share) for its stock offer to be acceptable, and that interest from the other unnamed parties is not expected to progress despite detailed discussions. These developments, along with Celltech's purchase of significantblocks of OGS shares makes Celltech's offer the only alternative, OGS' board and its advisor Goldman Sachs International (London, U.K.) believe. OGS said it had looked at breaking up the business, but decided there was no certainty that doing so wouldbring a higher value to shareholders than Celltech's offer.
展开▼
机译：Oxford Glycosciences pic（OGS）（英国牛津）表示，现在将向其股东Celltech Group pic（英国伯克郡Sllough）提出1.014亿英镑的收购要约，尽管OGS董事会仍认为该报价不反映该收购要约的价值。公司拥有的业务和现金。 OGS一直在与其他公司进行对话，包括Cambridge Antibody Technology Group pic（CAT）（英国剑桥），但表示自1月份提出收购要约以来，CAT的股价已过低（从540便士/股降至349.5便士） /股）以接受其股票要约，尽管进行了详细讨论，但其他未具名人士的利益预计不会增加。 OGS董事会及其顾问高盛国际（英国伦敦）认为，这些事态发展以及Celltech购买了大量OGS股份使Celltech的报价成为唯一的选择。 OGS表示已考虑分拆业务，但无法确定这样做能为股东带来比Celltech的要约更高的价值。
展开▼
